Welcome to CSNpharm! For Research Use Only!
Bcr-Abl
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN22517 | Target Protein-binding Moiety 8 | 910297-51-7 | PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl. |
| CSN12687 | Ponatinib | 943319-70-8 | Ponatinib is a potent multi-target inhibitor of Abl PDGFR VEGFR2 FGFR1 and Src with IC50 of 037 nM 11 nM 15 nM 22 nM and 54 nM respectively |
| CSN12740 | Lyn-IN-1 | 887650-05-7 | Lyn-IN-1 is a potent and selective dual Bcr-AblLyn inhibitor with potential antineoplastic activity it is an orally bioavailable 2-phenylaminopyrimidine derivative |
| CSN15689 | GNF-7 | 839706-07-9 | GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM respectively |
| CSN12398 | GNF-5 | 778277-15-9 | GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM its an analogue of GNF-2 with improved pharmacokinetic properties |
| CSN13825 | GNF-2 | 778270-11-4 | GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity IC50 014 M |
| CSN25549 | GMB-475 | 2490599-18-1 | GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations. |
| CSN16096 | DPH | 484049-04-9 | DPH is a potent cell permeable c-Abl activator which displays potent enzymatic and cellular activity in stimulating c-Abl activation |
| CSN16497 | Dasatinib | 302962-49-8 | Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. |
| CSN21248 | BCR-ABL-IN-1 | 188260-50-6 | BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase with a pIC50 of 646 and may be used in the research of chronic myelogenous leukemia |
| CSN19269 | Bafetinib | 859212-16-1 | Bafetinib is a potent and selective dual Bcr-AblLyn inhibitor with IC50 of 5.8 nM19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. |
| CSN25318 | AP23848 | 834894-21-2 | AP23848 is a potent Bcr-Abl inhibitor. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
